000301741 001__ 301741
000301741 005__ 20250829091627.0
000301741 0247_ $$2doi$$a10.1016/j.jshs.2025.101064
000301741 0247_ $$2pmid$$apmid:40447136
000301741 0247_ $$2ISSN$$a2095-2546
000301741 0247_ $$2ISSN$$a2213-2961
000301741 0247_ $$2altmetric$$aaltmetric:177665165
000301741 037__ $$aDKFZ-2025-01125
000301741 041__ $$aEnglish
000301741 082__ $$a610
000301741 1001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b0$$eFirst author$$udkfz
000301741 245__ $$aEffects of aerobic or resistance exercise during neoadjuvant chemotherapy on tumor response and therapy completion in women with breast cancer: The randomized controlled BENEFIT trial.
000301741 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2025
000301741 3367_ $$2DRIVER$$aarticle
000301741 3367_ $$2DataCite$$aOutput Types/Journal article
000301741 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1756451751_12784
000301741 3367_ $$2BibTeX$$aARTICLE
000301741 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000301741 3367_ $$00$$2EndNote$$aJournal Article
000301741 500__ $$a#EA:C110#LA:C110# / Volume 14, December 2025, 101064
000301741 520__ $$aThe potential of exercise as a concurrent therapy for actively treated primary tumors has been suggested by emerging preclinical and observational studies. However, clinical trials regarding this question are scarce. Therefore, we conducted a randomized controlled trial investigating the effects of aerobic or resistance exercise concomitant to neoadjuvant chemotherapy (NACT) on tumor size.IN THE BENEFIT STUDY (GERMAN TITLE: BEwegung bei NEoadjuvanter Chemotherapie zur Verbesserung der FITness), patients with breast cancer scheduled for NACT were randomly assigned to supervised resistance training (RT, n = 60) or aerobic training (AT, n = 60) twice weekly during NACT or to a waitlist control group (WCG, n = 60). The primary outcome, 'change in tumor size', as well as the secondary clinical outcomes pathologic complete response (pCR), type of surgery (breast conserving/mastectomy), axillary lymph node dissection (ALND, yes/no), premature discontinuation of chemotherapy (yes/no), and relative dose intensity (RDI) were derived from clinical records. Due to the highly skewed distribution, the primary outcome was categorized. Multiple (ordinal) logistic regression analyses were performed.Overall, there was no significant difference in post-intervention tumor size between RT or AT and WCG. However, there was a significant effect modification by hormone receptor (HR) status (pinteraction = 0.030). Among patients with HR+ tumors, results suggest a beneficial effect of AT on tumor shrinkage (odds ratio (OR) = 2.37, 95%CI: 0.97‒5.78), on pCR (OR = 3.21, 95%CI: 0.97‒10.61); and on ALND (OR = 3.76, 95%CI: 0.78‒18.06) compared to WCG. The effects of RT were slightly less pronounced. For HR- subtypes, beneficial effects on RDI were found for AT (OR = 3.71, 95%CI: 1.20‒11.50) and similarly for RT (OR = 2.58, 95%CI: 0.88‒7.59). Both AT and RT had favorable effects on premature discontinuation of chemotherapy (OR (no vs. yes) = 2.34, 95%CI: 1.10‒5.06), irrespective of tumor receptor status.While there was no significant effect on the primary outcome in the overall group, aerobic and resistance exercise concomitant to NACT seem to beneficially affect tumor shrinkage and pCR, reduce the need for ALND among patients with HR+ breast cancers, and prevent low RDI among patients with HR- breast cancers. These results warrant confirmation in further trials.
000301741 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000301741 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000301741 650_7 $$2Other$$aClinical cancer outcomes
000301741 650_7 $$2Other$$aNeoadjuvant chemotherapy
000301741 650_7 $$2Other$$aPathologic complete response
000301741 650_7 $$2Other$$aSupervised exercise
000301741 650_7 $$2Other$$aTumor response
000301741 7001_ $$0P:(DE-He78)f42e2297e771e17df08f2cc1171df9e4$$aGoldschmidt, Siri$$b1
000301741 7001_ $$0P:(DE-He78)e0edc48464c2d5afd09687075ebd532b$$aKreutz, Charlotte$$b2
000301741 7001_ $$aMüller, Jana$$b3
000301741 7001_ $$aSchneeweiss, Andreas$$b4
000301741 7001_ $$aMay, Anne M$$b5
000301741 7001_ $$aRosenberger, Friederike$$b6
000301741 7001_ $$aWiskemann, Joachim$$b7
000301741 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b8$$eLast author$$udkfz
000301741 773__ $$0PERI:(DE-600)2673028-5$$a10.1016/j.jshs.2025.101064$$gp. 101064 -$$p101064$$tJournal of sport and health science$$v14$$x2095-2546$$y2025
000301741 909CO $$ooai:inrepo02.dkfz.de:301741$$pVDB
000301741 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000301741 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)f42e2297e771e17df08f2cc1171df9e4$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000301741 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e0edc48464c2d5afd09687075ebd532b$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000301741 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000301741 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000301741 9141_ $$y2025
000301741 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2025-01-06$$wger
000301741 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ SPORT HEALTH SCI : 2022$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T08:49:36Z
000301741 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T08:49:36Z
000301741 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T08:49:36Z
000301741 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)1180$$2StatID$$aDBCoverage$$bCurrent Contents - Social and Behavioral Sciences$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)0130$$2StatID$$aDBCoverage$$bSocial Sciences Citation Index$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2025-01-06
000301741 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ SPORT HEALTH SCI : 2022$$d2025-01-06
000301741 9202_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Krebsprävention und Survivorship$$x0
000301741 9201_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Krebsprävention und Survivorship$$x0
000301741 9200_ $$0I:(DE-He78)C110-20160331$$kC110$$lBewegung, Krebsprävention und Survivorship$$x0
000301741 980__ $$ajournal
000301741 980__ $$aVDB
000301741 980__ $$aI:(DE-He78)C110-20160331
000301741 980__ $$aUNRESTRICTED